IN2014MN02213A - - Google Patents

Info

Publication number
IN2014MN02213A
IN2014MN02213A IN2213MUN2014A IN2014MN02213A IN 2014MN02213 A IN2014MN02213 A IN 2014MN02213A IN 2213MUN2014 A IN2213MUN2014 A IN 2213MUN2014A IN 2014MN02213 A IN2014MN02213 A IN 2014MN02213A
Authority
IN
India
Prior art keywords
formulations
incision
infiltration
api
administered
Prior art date
Application number
Other languages
English (en)
Inventor
Shimon Amselem
Michael Naveh
Original Assignee
Painreform Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Painreform Ltd filed Critical Painreform Ltd
Publication of IN2014MN02213A publication Critical patent/IN2014MN02213A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2213MUN2014 2012-05-10 2013-05-09 IN2014MN02213A (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645066P 2012-05-10 2012-05-10
US201261649400P 2012-05-21 2012-05-21
US201361781595P 2013-03-14 2013-03-14
US201361781625P 2013-03-14 2013-03-14
PCT/IL2013/050404 WO2013168167A1 (en) 2012-05-10 2013-05-09 Depot formulations of a hydrophobic active ingredient and methods for preparation thereof

Publications (1)

Publication Number Publication Date
IN2014MN02213A true IN2014MN02213A (da) 2015-07-10

Family

ID=49550270

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2214MUN2014 IN2014MN02214A (da) 2012-05-10 2013-05-09
IN2213MUN2014 IN2014MN02213A (da) 2012-05-10 2013-05-09

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN2214MUN2014 IN2014MN02214A (da) 2012-05-10 2013-05-09

Country Status (9)

Country Link
US (3) US9849088B2 (da)
EP (2) EP2846773A4 (da)
JP (4) JP2015516412A (da)
CN (2) CN104427977B (da)
AU (2) AU2013257608B2 (da)
CA (2) CA2871820C (da)
IN (2) IN2014MN02214A (da)
RU (2) RU2664700C2 (da)
WO (2) WO2013168167A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664700C2 (ru) * 2012-05-10 2018-08-21 Пейнреформ Лтд. Депо-составы местного анестетика и способы их получения
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2017009861A1 (en) * 2015-07-13 2017-01-19 Neon Laboratories Limited Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof
AU2018345844B2 (en) 2017-10-06 2024-03-07 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
JP7378929B2 (ja) * 2018-12-27 2023-11-14 花王株式会社 リポソームの製造方法
CN111388418B (zh) * 2018-12-31 2022-09-06 北京泰德制药股份有限公司 一种含有罗哌卡因或其药用盐的药物组合物
EP3991722A4 (en) * 2019-06-28 2022-10-05 Jiangsu Hengrui Medicine Co., Ltd. LIPID COMPOSITION WITH DELAYED RELEASE AND THEIR PROCESS OF PRODUCTION
US20230080811A1 (en) * 2020-01-14 2023-03-16 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
CN115463084B (zh) * 2021-06-10 2024-05-28 北京泰德制药股份有限公司 一种长效镇痛用复方油溶液制剂及其制备方法
WO2023043876A1 (en) * 2021-09-15 2023-03-23 Ocusoft, Inc. Ointments for treating dry skin
US20240065995A1 (en) * 2022-08-27 2024-02-29 Darren Alexander Rubin Injectable methods to treat deficiencies in glutathione metabolism and homocystinuria

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252793A (en) 1979-06-18 1981-02-24 American Lecithin Company Injectable lecithin preparation
JPH0753661B2 (ja) 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US5173219A (en) 1986-02-12 1992-12-22 Research Development Foundation Uniform spherical multilamellar liposomes of defined and adjustable size distribution
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
NZ223660A (en) 1987-03-05 1990-11-27 Liposome Co Inc Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity
CH681427A5 (da) 1987-07-01 1993-03-31 Zambon Spa
US5807572A (en) 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5576017A (en) 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
ATE182278T1 (de) * 1991-10-04 1999-08-15 Gs Dev Ab Teilchen, methode zur herstellung der teilchen und deren verwendung
SE9200952D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
EP0674506B1 (en) 1992-12-02 2000-08-23 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
JP3545403B2 (ja) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
SE9302218D0 (sv) * 1993-06-28 1993-06-28 Ab Astra New use
JP3479535B2 (ja) * 1993-07-08 2003-12-15 ザ リポソーム カンパニー、インコーポレーテッド リポソームの粒径を制御する方法
JP3002702B2 (ja) 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド 活性物質の制御放出を有する小胞
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
CZ293764B6 (cs) 1993-11-19 2004-07-14 Janssen Pharmaceutica N. V. Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití
US5635206A (en) 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
CA2153553A1 (en) 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
HU223475B1 (hu) * 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2230448A1 (en) * 1995-08-28 1997-03-06 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
EP0770387B1 (en) * 1995-10-28 1999-08-11 B. Braun Melsungen Ag Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic
US5744337A (en) * 1995-12-26 1998-04-28 The United States Of America As Represented By The Secretary Of The Navy Internal gelation method for forming multilayer microspheres and product thereof
FR2753626B1 (fr) 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
ES2343767T3 (es) 1997-09-18 2010-08-09 Pacira Pharmaceuticals, Inc. Composiciones anestesicas liposomicas de liberacion sostenida.
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU1297899A (en) 1997-10-31 1999-05-24 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
JP4575592B2 (ja) 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
JP2002520120A (ja) 1998-07-17 2002-07-09 スカイファーマ インコーポレーテッド 封入物質の制御放出のための生分解性組成物
DK0982035T3 (da) * 1998-08-18 2004-06-28 Panacea Biotec Ltd Cyclosporinpræparater
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
NZ515644A (en) 1999-06-04 2004-12-24 Skyepharma Inc Oil-core compositions for the sustained release of hydrophobic drugs
KR100343125B1 (ko) 1999-09-14 2002-07-05 임정옥 도포용 리포좀형 혼합국소마취제 및 그 제조방법
EP1138313A1 (de) 2000-03-28 2001-10-04 Primacare S.A. Pro-liposomen
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
IL139177A0 (en) 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
WO2002096368A2 (en) 2001-05-31 2002-12-05 Skyepharma Inc. Encapsulation of nanosuspensions in liposomes and microspheres
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
EP1461044A4 (en) 2001-12-03 2007-06-13 Novacea Inc PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE COMPOUNDS OF VITAMIN D
US20060014730A1 (en) 2002-04-10 2006-01-19 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20030236306A1 (en) 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7229630B2 (en) 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
WO2004024225A1 (en) 2002-09-16 2004-03-25 Zicam, Llc. System and method for delivering a composition to the nasal membrane
EP1551384A4 (en) 2002-10-07 2008-04-09 Encore Pharmaceuticals Inc R-NSAID ESTERS AND ITS USE
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050049209A1 (en) 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7968122B2 (en) 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050186230A1 (en) 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
EP1729784A1 (en) 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
RU2390331C2 (ru) * 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
CA2612006A1 (en) * 2004-06-15 2006-01-05 Encore Therapeutics, Inc. Phospholipid compositions and methods for their preparation and use
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
JP2008508302A (ja) 2004-07-28 2008-03-21 エスディー ファーマシューティカルズ インコーポレイティッド αコハク酸トコフェリル、そのアナログおよび塩の安定な注射用組成物
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
CN101257894A (zh) 2005-07-07 2008-09-03 法纳姆公司 高水溶性药物的缓释药物组合物
US20070078434A1 (en) * 2005-09-30 2007-04-05 Vyteris, Inc. Indications For Local Transport of Anaesthetic Agents By Electrotransport Devices
US20090221594A1 (en) 2005-12-02 2009-09-03 Chen Andrew X Stable pharmaceutical compositions of 5, 10 methylenetrahydrofolate
CN100518738C (zh) * 2006-01-06 2009-07-29 中国药科大学 一种含喜树碱类药物的自组装前体脂质体及其制备方法
CN100486569C (zh) 2006-01-06 2009-05-13 中国药科大学 一种多烯紫杉醇自组装前体脂质体及其制备方法
CN100563715C (zh) 2006-01-06 2009-12-02 中国药科大学 一种紫杉醇自组装前体脂质体及其制备方法
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
JP2010512341A (ja) * 2006-12-07 2010-04-22 リオトロピック セラピュティックス アイエヌシー． 麻酔薬および他の化合物の逆転および解毒用組成物ならびにその使用方法
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US20100041704A1 (en) 2007-01-12 2010-02-18 Aberg A K Gunnar Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus
ES2350029T3 (es) 2007-03-02 2011-01-17 Farnam Companies, Inc. Pellets de liberación sostenida que comprenden un material tipo cera.
EP2146692A1 (en) 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
BRPI0704542B8 (pt) 2007-05-15 2021-05-25 Univ Estadual Campinas Unicamp composição farmacêutica, processo de obtenção da composição farmacêutica, uso de uma quantidade farmaceuticamente eficaz de anestésico e agente gelificante, produto e método de tratamento
RU2429242C2 (ru) * 2007-05-30 2011-09-20 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) Применение тетранитрозильного комплекса железа с тиофенолом в качестве противоопухолевого лекарственного средства
HUP0700426A2 (en) 2007-06-19 2010-03-29 Invencio 21 Gyogyhatasu Keszit Liposomal compound
EP2178893A4 (en) 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc ORAL FORMULATIONS FOR PICOPLATIN
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
AU2009289464B2 (en) 2008-09-04 2015-12-10 Farnam Companies, Inc. Chewable sustained release formulations
CA2738630A1 (en) 2008-10-10 2010-04-15 Dara Biosciences, Inc. Methods for treating or preventing pain using spicamycin derivatives
US20100305500A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
JP2013503166A (ja) 2009-08-25 2013-01-31 カーディオカイン・バイオファーマ・エルエルシー 不溶性剤を送達するための組成物
EP2336286A1 (en) * 2009-12-18 2011-06-22 The Procter & Gamble Company Composition comprising microcapsules
CN102933200B (zh) * 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
WO2011096953A1 (en) 2010-02-05 2011-08-11 Cenerx Biopharma, Inc. Oral antidepressant formulation with reduced excipient load
US20140066481A1 (en) 2010-04-01 2014-03-06 Pharmanest Ab Water-Free Pharmaceutical Compositions Suitable for Local Anaesthetics
EP2555752B1 (en) 2010-04-09 2019-06-26 Pacira Pharmaceuticals, Inc. Method for formulating multivesicular liposomes
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2011153513A2 (en) 2010-06-03 2011-12-08 Latitude Pharma Nanoemulsion composition containing vitamin k
CA2803004A1 (en) 2010-06-29 2012-01-12 Poniard Pharmaceuticals, Inc. Oral formulations of kinase inhibitors
EP2593089B1 (en) 2010-07-14 2018-04-04 Senju Pharmaceutical Co., Ltd. Solid dispersion of alfa-ketoamide derivative
CA2809022C (en) 2010-08-20 2017-01-03 Dr. Reddy`S Laboratories, Inc. Phospholipid depot
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
AU2011317237B2 (en) 2010-10-22 2015-02-05 Dr. Reddy's Laboratories Sa Use of storage stable viscous phospholipid depot to treat wounds
CN103260702B (zh) 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂
EP2717853A4 (en) 2011-06-09 2014-11-05 Amylin Pharmaceuticals Llc COMPOSITIONS OF GELS
RU2664700C2 (ru) * 2012-05-10 2018-08-21 Пейнреформ Лтд. Депо-составы местного анестетика и способы их получения

Also Published As

Publication number Publication date
EP2846772A4 (en) 2015-12-30
JP2018035179A (ja) 2018-03-08
WO2013168172A1 (en) 2013-11-14
JP2015516411A (ja) 2015-06-11
EP2846773A1 (en) 2015-03-18
CN104427976A (zh) 2015-03-18
IN2014MN02214A (da) 2015-07-17
CA2871820C (en) 2020-11-03
JP6577548B2 (ja) 2019-09-18
WO2013168167A1 (en) 2013-11-14
CN104427976B (zh) 2018-04-24
AU2013257546B2 (en) 2017-12-14
AU2013257608A1 (en) 2014-11-27
RU2014144500A (ru) 2016-07-10
US9849088B2 (en) 2017-12-26
RU2678433C2 (ru) 2019-01-29
US9668974B2 (en) 2017-06-06
EP2846773A4 (en) 2015-12-30
JP2017222729A (ja) 2017-12-21
AU2013257608B2 (en) 2017-12-14
US20150148325A1 (en) 2015-05-28
CN104427977B (zh) 2018-02-02
CA2871821C (en) 2021-01-12
CN104427977A (zh) 2015-03-18
US20180049985A1 (en) 2018-02-22
CA2871820A1 (en) 2013-11-14
JP6574228B2 (ja) 2019-09-11
RU2664700C2 (ru) 2018-08-21
EP2846772A1 (en) 2015-03-18
AU2013257546A1 (en) 2014-11-27
US20150111923A1 (en) 2015-04-23
RU2014144501A (ru) 2016-07-10
US10206876B2 (en) 2019-02-19
JP2015516412A (ja) 2015-06-11
CA2871821A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
IN2014MN02213A (da)
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2021006035A (es) Formulaciones cannabinoides estables.
PH12016500024A1 (en) Bromodomain inhibitor
EP4285928A3 (en) Anti-pdl1 antibody formulations
MX2019003693A (es) Formulaciones de insulina de accion prolongada.
MX2014011181A (es) Microemulsiones basadas en ciclodextrina y usos dermatologicos de las mismas.
MX2016005395A (es) Formulacion estable de insulina glulisina.
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MD20150050A2 (ro) Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
EP4360621A3 (en) Formulations of bendamustine
IN2014DN00277A (da)
IN2014MN01470A (da)
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
PH12015502556A1 (en) Modified release formulation
EP2981258B8 (en) Pharmaceutical formulations for subcutaneous administration of furosemide
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2013100869A3 (en) Lipid-based nanocarrier systems for using cancer treatment
BR112017019364A2 (pt) dispersões sólidas
IN2014DN09246A (da)
GB201204632D0 (en) Delivery system
EP2668952A3 (en) Aqueous formulations of bisphosphonates, vitamin D and benzyl alcohol suitable for subcutaneous or intramuscular use
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин